SCHEMBL2183994

SCHEMBL2183994

CN1CCC(Nc2cc(NS(=O)(=O)c3ccccc3)ccc2Cl)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.49
HTR6 P50406 5/20 0.48
CYP2D6 P10635 2/20 0.48
BRD4 O60885 4/20 0.46
GAA P10253 1/20 0.45
GFER P55789 1/20 0.45
APOBEC3G Q9HC16 1/20 0.45
POLB P06746 1/20 0.45
DRD2 P14416 2/20 0.45
HTR2A P28223 2/20 0.45
HTR2C P28335 2/20 0.45
DRD3 P35462 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
TRIM24 O15164 1/20 0.44
JAK2 O60674 2/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6118475 0.99 CYP3A4 (0.48) CYP3A4HTR6CYP2D6BRD4GAA
SCHEMBL2183002 0.90 CYP3A4 (0.49) CYP3A4HTR6CYP2D6BRD4POLB
SCHEMBL2169741 0.89 HSD17B3 (0.49) CYP3A4HTR6CYP2D6BRD4POLB
SCHEMBL2169945 0.89 HTR6 (0.50) CYP3A4HTR6CYP2D6BRD4POLB
SCHEMBL2169936 0.88 HTR6 (0.49) CYP3A4HTR6CYP2D6POLBDRD2
SCHEMBL2185914 0.88 ALDH1A1 (0.50) CYP3A4HTR6BRD4POLBHTR2A
SCHEMBL2170725 0.87 CYP3A4 (0.50) CYP3A4HTR6BRD4GAAGFER
SCHEMBL2170411 0.87 CYP3A4 (0.58) CYP3A4HTR6CYP2D6BRD4GAA
SCHEMBL6118587 0.85 CYP3A4 (0.51) CYP3A4HTR6CYP2D6BRD4POLB
SCHEMBL2170708 0.84 HTR6 (0.63) CYP3A4HTR6CYP2D6DRD2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2346847-B1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LTD (IN) 2013-05-15 EP claimed
US-8404720-B2 Aryl sulfonamide amine compounds and their use as 5-HT6 ligands SUVEN LIFE SCIENCES LIMITED (IN) 2013-03-26 US claimed
US-20120129816-A1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2012-05-24 US claimed
EP-2346847-A1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS Suven Life Sciences Limited (IN) 2011-07-27 EP claimed
WO-2010032258-A1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2010-03-25 WO claimed
EP-2346847-B1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LTD (IN) 2013-05-15 EP disclosed
US-8404720-B2 Aryl sulfonamide amine compounds and their use as 5-HT6 ligands SUVEN LIFE SCIENCES LIMITED (IN) 2013-03-26 US disclosed
US-20120129816-A1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2012-05-24 US disclosed
EP-2346847-A1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS Suven Life Sciences Limited (IN) 2011-07-27 EP disclosed
WO-2010032258-A1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129816-A1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS HTR6, HTR1A, HTR5A CYP3A4 119/4885HTR6 1/4885CYP2D6 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.